Urine exosome marker combination for prostate cancer detection and application thereof

Through the detection of genes such as AMACR, FOXA1, MALAT1, etc. in urine exosomes, combined with prediction models, the limitations of existing prostate cancer screening methods are solved, non-invasive and accurate early screening is achieved, and detection rate is improved. accuracy.

CN118995920APending Publication Date: 2024-11-22SHENZHEN HUIXIN LIFE TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310557410.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-17
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing prostate cancer screening methods such as PSA detection and DRE examination have limitations, especially the nonspecific and invasiveness of PSA, which leads to inefficient early screening and may lead to overdiagnosis and treatment.

Method used

The combination of urinary exosome markers, including AMACR, FOXA1, MALAT1, SPDEF and other genes, was used to detect mRNA expression levels in exosomes in urine through real-time fluorescence quantitative PCR, and combined with prediction models, non-invasive and accurate early stages of prostate cancer. Screening.

Benefits of technology

It significantly improves the detection rate of prostate cancer, is non-invasive, rapid and accurate, improves the accuracy and sensitivity of early screening, and reduces the risk of overdiagnosis and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995920A_ABST
    Figure CN118995920A_ABST
Patent Text Reader

Abstract

The invention provides a urine exosome marker combination for prostate cancer detection, and the urine exosome marker combination comprises AMACR and a reference gene, as well as one, two or three genes selected from FOXA1, MALAT1, DLX1, HOCX6, PSMA, PCA3 and TTTY15-USP9Y. Combining the markers to construct a prediction model, training the model through a training set, optimizing the model through a test verification set, and finally obtaining an early prediction model of the prostatic cancer. Specific primers and probes are respectively designed aiming at the marker combination, and fluorescent quantitative PCR is combined, so that urine exosome marker detection and cancer and non-cancer classification and screening can be carried out on a subject. The random urine sample is obtained on the basis of a non-invasive method, the tumor detection rate can be obviously increased by jointly detecting expression of the prostate cancer related marker genes, and the method has the advantages of being non-invasive, accurate and rapid.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomolecule detection, and in particular to a urine exosome marker combination for prostate cancer detection and an application thereof. Background Art

[0002] Prostate cancer is one of the most common malignant tumors of the male reproductive system. The survival time of prostate cancer patients is closely related to the stage of malignant tumors at the time of clinical diagnosis. Therefore, "early screening, early diagnosis, and early treatment" for high-risk groups of prostate cancer is an effective way to improve the overall survival rate of prostate cancer patients in China.

[0003] Extracellular vesicles (EVs) are vesicles with a phospholipid bilayer structure secreted by cells. They can regulate the biological characteristics of receptor cells through the biomacromolecules they carry, and participate in the physiological and pathological processes of cells. Exosomes are an important subgroup of EVs, which contain substances such as proteins, mRNA and microRNA. They are the medium for close communication between healthy and diseased cells, and are involved in multiple processes such as tumor occurrence, development, invasion and metastasis. At the same time, compared with other body fluids, urine has the characteristics of safe sampling, large sample size and non-invasiveness. Studies have found that urine exosome RNA can be used as a marker to effectively detect urinary system cancer.

[0004] Currently, prostate-specific antigen (PSA) and digital rectal examination (DRE) are the main tools used to screen for prostate cancer in men, but both have inherent limitations. PSA is not cancer-specific, and PSA levels can be elevated in non-cancerous conditions such as benign prostatic hyperplasia (BPH), prostatitis, or lower urinary tract infection. When PSA is between 4 and 10 ng / mL, the positive puncture rate is only about 20%; when PSA is between 10 and 20 ng / ml, the positive puncture rate is only about 30%. DRE relies too much on the doctor's experience and is an invasive and intrusive examination. How to improve the positive rate of puncture while avoiding overdiagnosis and treatment is a huge challenge in the early screening of prostate cancer. Summary of the invention

[0005] To address the deficiencies of the prior art, the present application provides a urine exosome marker combination and kit for early detection of prostate cancer, which obtains random urine samples by a non-invasive method, and does not require DRE before collection of urine samples, nor does it require separation of cell precipitates from urine samples. By jointly detecting the expression of prostate cancer-related genes, the tumor detection rate can be significantly improved, and it has the characteristics of being non-invasive, accurate, and rapid.

[0006] To achieve the above objectives, the technical solutions adopted by the present invention include:

[0007] The invention discloses a urine exosome marker combination for prostate cancer detection, wherein the marker comprises AMACR and an internal reference gene, and one, two or three genes selected from FOXA1, MALAT1, DLX1, HOCX6, PSMA, PCA3 and TTTY15-USP9Y.

[0008] Preferably, the markers include AMACR and an internal reference gene, and one or two genes selected from FOXA1 and MALAT1.

[0009] Preferably, the markers are AMACR, internal reference genes, FOXA1 and MALAT1.

[0010] Preferably, the internal reference gene is selected from one of SPDEF and KLK3.

[0011] The present invention discloses an amplification primer set for amplifying the urine exosome marker, wherein the primer set comprises: a primer for amplifying AMACR, wherein the upstream primer sequence is shown in SEQ ID NO:1, and the downstream primer sequence is shown in SEQ ID NO:2; a primer for amplifying FOXA1, wherein the upstream primer sequence is shown in SEQ ID NO:4, and the downstream primer sequence is shown in SEQ ID NO:5; a primer for amplifying MALAT1, wherein the upstream primer sequence is shown in SEQ ID NO:7, and the downstream primer sequence is shown in SEQ ID NO:8; a primer for amplifying HOCX6, wherein the upstream primer sequence is shown in SEQ ID NO:13, and the downstream primer sequence is shown in SEQ ID NO:14; a primer for amplifying DLX1, wherein the upstream primer sequence is shown in SEQ ID NO:19, and the downstream primer sequence is shown in SEQ ID NO:20; a primer for amplifying PSMA, wherein the upstream primer sequence is shown in SEQ ID NO:22, and the downstream primer sequence is shown in SEQ ID NO:23; a primer for amplifying PCA3, wherein the upstream primer sequence is shown in SEQ ID NO: The upstream primer sequence is shown in SEQ ID NO:25, and the downstream primer sequence is shown in SEQ ID NO:26; the primer for amplifying TTTY15-USP9Y, the upstream primer sequence is shown in SEQ ID NO:28, and the downstream primer sequence is shown in SEQ ID NO:29.

[0012] Preferably, the primer set further includes: a primer for amplifying the internal reference gene SPDEF, whose upstream primer sequence is shown in SEQ ID NO: 10, and whose downstream primer sequence is shown in SEQ ID NO: 11; a primer for amplifying the internal reference gene KLK3, whose upstream primer sequence is shown in SEQ ID NO: 16, and whose downstream primer sequence is shown in SEQ ID NO: 17.

[0013] Preferably, it also includes detection probes, wherein the probe sequence for detecting AMACR is shown in SEQ ID NO:3, the probe sequence for detecting FOXA1 is shown in SEQ ID NO:6, the probe sequence for detecting MALAT1 is shown in SEQ ID NO:9, the probe sequence for detecting SPDEF is shown in SEQ ID NO:12, the probe sequence for detecting HOCX6 is shown in SEQ ID NO:15, the probe sequence for detecting KLK3 is shown in SEQ ID NO:18, the probe sequence for detecting DLX1 is shown in SEQ ID NO:21, the probe sequence for detecting PSMA is shown in SEQ ID NO:24, the probe sequence for detecting PCA3 is shown in SEQ ID NO:27, and the probe sequence for detecting TTTY15-USP9Y is shown in SEQ ID NO:30.

[0014] Preferably, the detection probe is labeled with a fluorescent reporter group, and the fluorescent reporter group is selected from FAM, HEX, ROX, VIC, CY5, 5-TAMRA, TET, CY3 and JOE.

[0015] The invention discloses the use of the marker combination and the amplification primer group in preparing a detection reagent for detecting prostate cancer.

[0016] Preferably, the detection is achieved by detecting exosomes in the patient's urine.

[0017] The invention discloses a kit for detecting prostate cancer, and the kit comprises the amplification primer set.

[0018] Preferably, the kit further comprises a reagent for extracting urine exosomes.

[0019] The present invention discloses a urine exosome marker combination for prostate cancer detection, wherein the markers include: DLX1, HOCX6, FOXA1, MALAT1, PSMA, AMACR, PCA3, TTTY15-USP9Y, and an internal reference gene, wherein the internal reference gene may be SPDEF or KLK3.

[0020] Preferably, the marker combination comprises at least AMACR, FOXA1 and SPDEF, or the marker combination comprises at least AMACR, MALAT1 and SPDEF.

[0021] The present invention discloses an amplification primer set for amplifying the urine exosome marker, wherein the primer set comprises: a primer for amplifying AMACR, wherein the upstream primer sequence is shown in SEQ ID NO:1, and the downstream primer sequence is shown in SEQ ID NO:2; a primer for amplifying FOXA1, wherein the upstream primer sequence is shown in SEQ ID NO:4, and the downstream primer sequence is shown in SEQ ID NO:5; a primer for amplifying MALAT1, wherein the upstream primer sequence is shown in SEQ ID NO:7, and the downstream primer sequence is shown in SEQ ID NO:8.

[0022] Preferably, the primer set further comprises: a primer for amplifying SPDEF, whose upstream primer sequence is shown as SEQ ID NO:10, and whose downstream primer sequence is shown as SEQ ID NO:11.

[0023] Preferably, it further comprises detection probes, wherein the probe sequence for detecting AMACR is shown in SEQ ID NO:3, the probe sequence for detecting FOXA1 is shown in SEQ ID NO:6, the probe sequence for detecting MALAT1 is shown in SEQ ID NO:9, and the probe sequence for detecting SPDEF is shown in SEQ ID NO:12.

[0024] Preferably, the detection probe is labeled with a fluorescent reporter group, and the fluorescent reporter group is selected from FAM, HEX, ROX, VIC, CY5, 5-TAMRA, TET, CY3 and JOE.

[0025] Preferably, the fluorescent group of the probe shown in SEQ ID NO:3 is FAM; the fluorescent group of the probe shown in SEQ ID NO:6 is ROX; the fluorescent group of the probe shown in SEQ ID NO:9 is CY5; and the fluorescent group of the probe shown in SEQ ID NO:12 is HEX.

[0026] Preferably, the quencher group of the probe shown in SEQ ID NO:3 of the present application is BHQ1; in a specific embodiment, the quencher group of the probe shown in SEQ ID NO:6 of the present application is BHQ2; in a specific embodiment, the quencher group of the probe shown in SEQ ID NO:12 of the present application is MGB.

[0027] The invention discloses the use of the marker combination and the amplification primer group in preparing a detection reagent for detecting prostate cancer.

[0028] Preferably, the detection is achieved by detecting exosomes in the patient's urine.

[0029] The invention discloses a kit for detecting prostate cancer, and the kit comprises the amplification primer set.

[0030] Preferably, the test sample of the kit is exosomes in patient urine.

[0031] Preferably, the kit further comprises a reagent for extracting urine exosomes.

[0032] Preferably, the kit further comprises a positive quality control product and a negative quality control product.

[0033] In a first aspect, the present application provides a urine exosome marker combination for early detection of prostate cancer, characterized in that the markers include urine exosome mRNA biomarkers, the urine exosome mRNA biomarkers are DLX1, HOCX6, FOXA1, MALAT1, PSMA, AMACR, PCA3, TTTY15-USP9Y, and an internal reference gene, and the internal reference gene can be SPDEF or KLK3.

[0034] Furthermore, the expression value of the urinary exosome mRNA biomarker in the urinary exosomes of prostate cancer patients is statistically significantly different from that in the control sample.

[0035] In the second aspect, the present application provides a prostate cancer prediction model based on a combination of urinary exosome biomarkers. The algorithm of the model is:

[0036] Output value = {Ct(Target 1)-Ct(Internal reference)}×a+{Ct(Target 2)-Ct(Internal reference)}×b+{Ct(Target 3)-Ct(Internal reference)}×c+……+{Ct(Target N)-Ct(Internal reference)}×n+m

[0037] Where a, b, c and n are coefficients, and m is a constant, which can be determined by fitting the output of the equation to an existing data set through logistic regression or linear regression. Coefficient a is between 0 and 1; coefficient b is between 0 and 1, preferably; coefficient c is between 0 and 1; coefficient n is between 0 and 1; constant m is between 0 and 1.

[0038] In some embodiments, the output value of the above algorithm is used to predict whether the patient is in a low risk of prostate cancer or a high risk of prostate cancer. For example, a patient whose output value calculated using the above algorithm is less than 0.25 is identified as having a lower risk of prostate cancer, and an output value equal to or higher than 0.25 is identified as having a higher risk of prostate cancer.

[0039] The exosome marker combination and prediction model provided in Example 3 of the present application can more accurately perform early screening of clinical samples with PSA between 4 and 20 ng / mL, such as Figure 3As shown, the marker combination AMACR+FOXA1+MALAT1 has an AUC of 0.9026, a sensitivity of 85.5%, a specificity of 82.4%, and an accuracy of 83.5%, which has good clinical diagnostic value.

[0040] In a third aspect, the present application provides a kit for early detection of prostate cancer. The kit is used to detect the mRNA expression levels of AMACR, FOXA1, MALAT1 and SPDEF in urine exosomes, and then the output value is calculated using the above-mentioned prostate cancer prediction model and compared with the cutoff value to analyze the risk of prostate cancer in the subject.

[0041] Furthermore, the kit of the present application includes the following components: an RT-qPCR reaction solution containing primers and probes that specifically recognize the mRNA sequences of AMACR, FOXA1, MALAT1 and SPDEF, an enzyme mixture containing reverse transcriptase, DNA polymerase, and UDG enzyme, a positive quality control product, and a negative quality control product.

[0042] Furthermore, the kit of the present application provides a set of primers and probe combinations for detecting prostate cancer urine exosome markers, the combination comprising primers and probes for detecting the mRNA of AMACR, FOXA1, MALAT1 and SPDEF, respectively, including:

[0043] AMACR upstream primer: 5'-GGGCTCGTTTATCACCAGTGA-3' SEQ ID NO: 1;

[0044] AMACR downstream primer: 5'-CGGCTGAATCCAAATTCTTCA-3' SEQ ID NO: 2;

[0045] AMACR probe: 5'-CCCGCCCTGCACCTCTGCTGTTA-3'

[0046] SEQ ID NO:3;

[0047] FOXA1 upstream primer: 5'-GGCATGAAACCAGCGACT-3' SEQ ID NO: 4;

[0048] FOXA1 downstream primer: 5'-TGGTGTTCATGGTCATGTAGGT-3'

[0049] SEQ ID NO: 5;

[0050] FOXA1 probe: 5'-CCCGGTCAGCAACATGAACTCAGG-3' SEQ ID NO: 6;

[0051] MALAT1 upstream primer: 5'-CCCCGTGCCTTTTGATCTAG-3' SEQ ID NO: 7;

[0052] MALAT1 downstream primer: 5'-CATGCCCACAAGGATCCAA-3' SEQ ID NO: 8;

[0053] MALAT1 probe: 5'-CCCCTCACCTCGATGCAGCCA-3' SEQ ID NO: 9;

[0054] SPDEF upstream primer: 5'-GGCGAAGTGCTCAAGGACAT-3' SEQ ID NO: 10;

[0055] SPDEF downstream primer: 5'-CAGGAGCCACTTCTGCACATT-3' SEQ ID NO: 11;

[0056] SPDEF probe: 5'-ACGGCCTGCAAGCTGCTCAACATC-3' SEQ ID NO: 12;

[0057] HOCX6 upstream primer: 5'-CCAGAAAGCCAGTATCCAGATTTAC-3' SEQ ID NO: 13;

[0058] HOCX6 downstream primer: 5'-TCTGGTACCGCGAGTAGAT-3' SEQ ID NO: 14;

[0059] HOCX6 probe: 5'-TAGCCGACCCCACTGTGCGAATT-3' SEQ ID NO: 15;

[0060] KLK3 upstream primer: 5'-ACCAGAGGAGTTCTTGAC-3' SEQ ID NO: 16,

[0061] KLK3 downstream primer: 5'-CAGCATGAAC TTGGTCAC-3' SEQ ID NO: 17

[0062] KLK3 probe: 5'-AGAAACTTCAGTGTGTGGACCTCC-3' SEQ ID NO: 18;

[0063] DLX1 upstream primer: 5'-TCAGCTTTACAACAATCCCTA-3' SEQ ID NO: 19,

[0064] DLX1 downstream primer: 5'-CAGTCATTAGATCCTGCA-3' SEQ ID NO: 20,

[0065] DLX1 probe: 5'-ACCACAGAATAATGCCAGTCACCAC-3' SEQ ID NO: 21;

[0066] PSMA upstream primer: 5'-TGCACAGAAGCTCCTAGAAAAAATG-3'

[0067] SEQ ID NO:22

[0068] PSMA downstream primer: 5'-TTCCAGTAAAGCCAGGTCCAA-3' SEQ ID NO: 23;

[0069] PSMA probe: 5'-TGGCTCAGCACCACCAGATAGCAGC-3'SEQ ID NO: 24;

[0070] PCA3 upstream primer: 5'-GCTGGAAATGGACAACCAC-3' SEQ ID NO: 25;

[0071] PCA3 downstream primer: 5'-CCAGCTGAGACCTAATGCAAG-3' SEQ ID NO: 26

[0072] PCA3 probe: 5'-ACCCACAAATGCGAGGTGCTTC-3' SEQ ID NO: 27;

[0073] TTTY15-USP9Y upstream primer: 5-CCCTTGGAAAAACTGGCCTCATA-3' SEQ ID NO: 28,

[0074] TTTY15-USP9Y downstream primer: 5'-GCCTATCAATTGCTGCCTTATATA-3' SEQ ID NO: 29,

[0075] TTTY15-USP9Y probe: 5'-ACACATACTCCACACAGCCACCAGAAT-3' SEQ ID NO:30.

[0076] In the present application, the probe fluorescent reporter group can be selected from FAM, HEX, ROX, VIC, CY5, 5-TAMRA, TET, CY3 and JOE, but is not limited thereto.

[0077] In some specific embodiments, the fluorescent group of the probe shown in SEQ ID NO:3 of the present application is FAM; the fluorescent group shown in SEQ ID NO:6 is ROX; the fluorescent group of the probe shown in SEQ ID NO:9 is CY5; the fluorescent group shown in SEQ ID NO:12 is HEX.

[0078] Furthermore, the 3' end of the probe also has a quencher group, such as BHQ1, BHQ2, or MGB.

[0079] In a specific embodiment, the quencher group of the probe shown in SEQ ID NO:3 of the present application is BHQ1; in a specific embodiment, the quencher group of the probe shown in SEQ ID NO:6 and SEQ ID NO:9 of the present application is BHQ2; in a specific embodiment, the quencher group of the probe shown in SEQ ID NO:12 of the present application is MGB;

[0080] In a specific embodiment, the fluorescent group of the probe shown in SEQ ID NO: 15 is

[0081] FAM, the quencher group is BHQ1; the fluorescent group of SEQ ID NO:18 is HEX, and the quencher group is BHQ1; the fluorescent group of the probe of SEQ ID NO:21 is ROX, and the quencher group is BHQ2; the fluorescent group of the probe of SEQ ID NO:24 is FAM, and the quencher group is BHQ1; the fluorescent group of SEQ ID NO:27 is HEX, and the quencher group is BHQ1; the fluorescent group of the probe of SEQ ID NO:30 is CY5, and the quencher group is BHQ2;

[0082] Furthermore, the final concentration of the primers in the composition in the RT-PCR reaction system is 0.05 μM to 0.5 μM, preferably 0.2 μM; the final concentration of the probe in the composition in the RT-PCR reaction system is 0.05 μM to 0.3 μM, preferably 0.15 μM. The RT-PCR reaction system also includes Tris buffer, magnesium ions, and dA / G / C / UTPs. The final concentration of magnesium ions is 5 mM, the final concentration of dATP is 0.4 mM, the final concentration of dCTP is 0.4 mM, the final concentration of dGTP is 0.4 mM, and the final concentration of dUTP is 0.8 mM.

[0083] The present invention also relates to a method for using the above-mentioned kit in a kit for early diagnosis of prostate cancer by the following method, characterized in that the method comprises the following steps:

[0084] a) Collect random urine samples from patients suspected of prostate cancer, starting from the first urine passage, with a volume of 20 to 50 mL;

[0085] b) Isolation and purification of exosomes from urine samples;

[0086] c) extracting RNA from exosomes;

[0087] d) performing fluorescent quantitative PCR amplification on the obtained nucleic acid using the primer and probe combination and kit for the AMACR, FOXA1, MALAT1 and SPDEF genes of the present application;

[0088] e) obtaining the expression value of the corresponding biomarker, using the above-mentioned prostate cancer prediction model of the present application,

[0089] Assess the subjects' cancer risk.

[0090] The expression values ​​of the AMACR, FOXA1, MALAT1 and SPDEF biomarker combination provided in the present application in the urine exosomes of prostate cancer patients are statistically significantly different from those in the control samples. The marker combination is used to construct a prediction model, the model is trained by a training set, and the model is optimized by a test validation set, and finally an early prediction model for prostate cancer is obtained.

[0091] Specific primers and probes are designed for the markers or marker combinations with the highest AUC, combined with the necessary components of fluorescent quantitative PCR, to detect urine exosome markers in subjects, and the subjects are classified and screened for cancer and non-cancer using an early prediction model for prostate cancer.

[0092] This application collects urine samples non-invasively and detects exosomes, analyzes the expression of mRNA related to prostate cancer in exosomes, and establishes a prostate cancer early screening prediction model through logistic regression. The constructed prostate cancer early screening prediction model has the characteristics of high sensitivity and high specificity, and the model can eventually be used to classify and screen single or multiple samples for cancer and non-cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0093] Figure 1 . The ROC curve of the training set was plotted with the true positive rate (sensitivity) as the ordinate and the false positive rate (1-specificity) as the abscissa, and the AUC values ​​of the training set of different exosome marker combinations.

[0094] a. The AUC of the marker combination AMACR+FOXA1 was 0.8069;

[0095] b. The AUC of the marker combination AMACR+FOXA1+TTTY15-USP9Y was 0.9085;

[0096] c. The AUC of the marker combination AMACR+FOXA1+HOCX6 was 0.9146;

[0097] d. The AUC of the marker combination AMACR+FOXA1+DLX1 was 0.9216;

[0098] e. The AUC of the marker combination AMACR+FOXA1+PCA3 was 0.9307;

[0099] f. The AUC of the marker combination AMACR+FOXA1+PSMA was 0.9541;

[0100] g. The AUC of the marker combination AMACR+FOXA1+MALAT1 was 0.9638;

[0101] Figure 2 . The ROC curve of the training set was plotted with the true positive rate (sensitivity) as the ordinate and the false positive rate (1-specificity) as the abscissa, and the AUC values ​​of the training set for different exosome marker combinations.

[0102] a. The AUC of the marker combination AMACR+MALAT1 was 0.7916;

[0103] b. The AUC of the marker combination AMACR+MALAT1+TTTY15-USP9Y was 0.8912;

[0104] c. The AUC of the marker combination AMACR+MALAT1+PSMA was 0.9033;

[0105] d. The AUC of the marker combination AMACR+MALAT1+HOCX6 was 0.9150;

[0106] e. The AUC of the marker combination AMACR+MALAT1+DLX1 was 0.9227;

[0107] f. The AUC of the marker combination AMACR+MALAT1+PCA3 was 0.9347;

[0108] Figure 3 . ROC curve of the training set plotted with true positive rate (sensitivity) as the ordinate and false positive rate (1-specificity) as the abscissa, and AUC values ​​of the validation set of different exosome marker combinations.

[0109] a. The AUC of the marker combination AMACR+FOXA1 was 0.7501;

[0110] b. The AUC of the marker combination AMACR+FOXA1+TTTY15-USP9Y was 0.8481;

[0111] c. The AUC of the marker combination AMACR+FOXA1+HOCX6 was 0.8698;

[0112] d. The AUC of the marker combination AMACR+FOXA1+DLX1 was 0.8775;

[0113] e. The AUC of the marker combination AMACR+FOXA1+PCA3 was 0.8767;

[0114] f. The AUC of the marker combination AMACR+FOXA1+PSMA was 0.8990;

[0115] g. The AUC of the marker combination AMACR+FOXA1+MALAT1 was 09026;

[0116] Figure 4 . ROC curve of the training set plotted with the true positive rate (sensitivity) as the ordinate and the false positive rate (1-specificity) as the abscissa, and the AUC values ​​of the validation set for different exosome marker combinations.

[0117] a. The AUC of the marker combination AMACR+MALAT1 was 0.7302;

[0118] b. The AUC of the marker combination AMACR+MALAT1+TTTY15-USP9Y was 0.8550;

[0119] c. The AUC of the marker combination AMACR+MALAT1+PSMA was 0.8566;

[0120] d. The AUC of the marker combination AMACR+MALAT1+HOCX6 was 0.8625;

[0121] e. The AUC of the marker combination AMACR+MALAT1+DLX1 was 0.8776;

[0122] f. The AUC of the marker combination AMACR+MALAT1+PCA3 was 0.8894;

[0123] Figure 5 The validation set ROC curve was plotted with the true positive rate (sensitivity) as the ordinate and the false positive rate (1-specificity) as the abscissa. The validation set AUC value of the exosome marker combination was 0.9026. At the same time, when PSA was between 4 and 20 ng / mL, the AUC was 0.6697.

[0124] Figure 6.Results of screening for differentially expressed genes.

[0125] Figure 7 .Showing Brownian motion of particles in solution. Initial visual inspection indicated the presence of larger particles or aggregates.

[0126] Figure 8 The NTA software rapidly generates high-resolution particle-by-particle size distributions as well as counts of observed vesicle particles.

[0127] Fig. 9 .Amplification curve of prostate cancer positive samples detected by reaction combination 1 (HOCX6+DLX1+KLK3).

[0128] Fig.10 .Amplification curve of prostate cancer positive samples detected by reaction combination 2 (AMACR+FOXA1+MALAT1+SPDEF).

[0129] Fig.11 .Amplification curve of reaction combination 3 (PSMA+PCA3+TTTY15-USP9Y) detecting prostate cancer positive samples.

[0130] Fig.12 .Amplification curve of reaction combination 1 (HOCX6+DLX1+KLK3) detecting prostate cancer negative samples.

[0131] Fig.13 .Amplification curve of reaction combination 2 (AMACR+FOXA1+MALAT1+SPDEF) detecting prostate cancer negative samples.

[0132] Fig.14 .Amplification curve of reaction combination 3 (PSMA+PCA3+TTTY15-USP9Y) detecting prostate cancer negative samples. DETAILED DESCRIPTION

[0133] The specific implementation of the present invention is described in detail below in conjunction with the accompanying drawings. It should be understood that the specific implementation described here is only used to illustrate and explain the present invention, and is not used to limit the present invention.

[0134] The present application provides a urine exosome marker combination and kit for early detection of prostate cancer, and its specific implementation method includes the following steps:

[0135] (1) Obtain urine samples from different groups of subjects. The different groups of subjects include patients diagnosed with prostate cancer and patients ruled out of prostate cancer. The urine sample is the first urine discharged from the bladder, also known as "first-pass urine", and the collection volume is 20 to 50 mL.

[0136] (2) Extraction and characterization of exosomes in urine samples. In particular, the exosomes extracted using our patented product, the EXODUS exosome purification system (patent publication number: CN114616054A), have the characteristics of high purity, high yield, and complete morphology.

[0137] For those skilled in the art, the method for extracting exosomes is not limited to the above-mentioned operating steps. Suitable methods in the prior art such as ultracentrifugation, gradient density centrifugation, ultrafiltration centrifugation, magnetic bead immunoassay, etc., as well as the use of other commercial exosome precipitation agents are all feasible. Those skilled in the art can foresee that the exosomes obtained should have similar characteristics without differences due to changes in the extraction method.

[0138] In order to detect the characteristics of exosomes in the urine of prostate cancer patients and non-prostate cancer patients, this application uses Zetaview (brand: Particle Metrix) to test the concentration and particle size of exosomes. The method is Nanoparticle Tracking Analysis (NTA), which uses the characteristics of light scattering and Brownian motion to obtain the particle size distribution and particle concentration of sample nanoparticles in liquid suspension. The test results are as follows Figure 7 and Figure 8 shown.

[0139] (3) Exosome RNA extraction

[0140] This application uses a magnetic bead method nucleic acid extraction reagent to extract total exosome RNA. The specific operation process can refer to the public instructions for use of the product. For quality control of the extracted RNA quality, the quality of the extracted nucleic acid can be evaluated by comparing the ratio of the absorbance values ​​of the nucleic acid sample at 260nm and 280nm (A260 / A280). A260 / A280 is preferably 1.8 to 2.2, and more preferably 2.0.

[0141] (3) Detection of nucleic acid biomarkers

[0142] The present application uses a real-time fluorescence quantitative PCR method to measure the expression level of biomarkers in the above extracted RNA. The biomarkers at least include AMACR, FOXA1, MALAT1 and SPDEF genes.

[0143] (4) Analysis of biomarker mRNA expression levels

[0144] In the methods provided herein, the expression level of biomarker mRNA is determined by real-time fluorescence quantitative PCR analysis, and positive reactions are detected by the accumulation of fluorescent signals. The Ct value is defined as the number of cycles required for the fluorescent signal to exceed the threshold. The Ct value is inversely proportional to the amount of nucleic acid in the sample, that is, the smaller the Ct value, the greater the amount of nucleic acid in the sample.

[0145] In the method provided herein, the expression level of the detected gene is used to calculate the relative expression level of the gene collectively referred to as the reference gene, which is used to normalize the signal value of the detected gene to control the difference between the amount of exosomes extracted between samples, the performance of reagent components, and the performance of fluorescent quantitative PCR instruments. Reference genes are usually present in urine exosomes, and the reference genes used for normalizing the expression of markers DLX1, HOCX6, FOXA1, MALAT1, PSMA, AMACR, PCA3, TTTY15-USP9Y are prostate-specific genes, such as KLK3 and SPDEF. Relative expression level analysis or normalization is completed by subtracting the Ct value of the reference gene from the Ct value of DLX1, HOCX6, FOXA1, MALAT1, PSMA, AMACR, PCA3, TTTY15-USP9Y, respectively, and the result is called ΔCt, for example:

[0146] ΔCt (AMACR) =Ct (AMACR) -Ct (SPDEF) or ΔCt (AMACR) =Ct (AMACR) -Ct (KLK3)

[0147] (5) Biomarker mining

[0148] The urine samples obtained from different groups of subjects were divided into two groups, namely the cancer group and the non-cancer group. Based on the relative expression levels of each marker in the cancer group and the non-cancer group, statistical methods were used to mine mRNA biomarkers that can be used to distinguish prostate cancer from non-prostate cancer. The process is as follows: The independent sample t-test method in GraphPad Prism software was used to analyze the markers with significant differences in relative expression levels between the cancer group and the non-cancer group as candidate markers for subsequent analysis.

[0149] (6) Construction of a prostate cancer prediction model

[0150] Receiver operating characteristic (ROC curve) is a kind of widely used tool for the identification and diagnostic ability of assessment biomarker.The area under ROC curve (AUC) is set up to assess the diagnostic value of each biomarker or marker combination.The biomarker or marker combination with the highest diagnostic value has an AUC value greater than 0.6,0.7 or 0.8.Preferably, biomarker or marker combination has an AUC value greater than 0.85.As shown in Figure 1, when measuring the AUC=0.9638 of the score created by logistic regression analysis for AMACR, FOXA1, MALAT1 combination together, the expression level detected has the highest diagnostic accuracy.

[0151] Furthermore, the normalized expression levels of the above combination of AMACR, FOXA1, and MALAT1 with higher diagnostic value were used to establish a mathematical expression through data analysis, and a prostate cancer early diagnosis model was constructed by combining the sensitivity and specificity required for clinical application. The algorithm of this model is:

[0152] Output value={Ct(FOXA1)-Ct(SPDEF)}×a+{Ct(AMACR)-Ct(SPDEF)}×b+{Ct(MALAT1)+Ct(SPDEF)}×c+d.

[0153] Where a, b, c are coefficients, and d is a constant, which can be determined by fitting the output value of the equation to the existing data set through logistic regression or linear regression. Coefficient a is between 0 and 1, preferably, coefficient a=0.182; coefficient b is between 0 and 1, preferably, coefficient b=0.364; coefficient c is between 0 and 1, preferably, coefficient c=0.140; constant d is between 0 and 1, preferably, constant d=0.573.

[0154] The output value is used to distinguish the risk of prostate cancer in subjects through the cutoff value determined by the ROC curve. A value higher than the cutoff value indicates a higher risk of prostate cancer, while a value lower than the cutoff value indicates a lower risk of prostate cancer. The prostate cancer risk tips obtained by this method help doctors decide on the next diagnostic option for patients.

[0155] Example 1 Prostate Cancer Detection Kit Amplifies Urine Exosome Biomarkers

[0156] The target combination screening of 10 tumor markers in the exosomes of a prostate cancer detection kit is performed, comprising a PCR reaction solution for RT-qPCR amplification, wherein the PCR reaction solution comprises a set of primers and probe combinations for detecting 10 markers of prostate cancer urine exosomes, wherein the primers and probe combinations comprise: a primer pair for amplifying the AMACR gene at a concentration of 0.4 μM (SEQ ID NO: 1, SEQ ID NO: 2), and a probe for amplifying the AMACR gene at a concentration of 0.2 μM (SEQ ID NO: 3); a primer pair for amplifying the FOXA1 gene at a concentration of 0.2 μM (SEQ ID NO: 4, SEQ ID NO: 5), and a probe for amplifying the FOXA1 gene at a concentration of 0.1 μM (SEQ ID NO: 6); a primer pair for amplifying the MALAT1 gene at a concentration of 0.3 μM (SEQ ID NO: 7, SEQ ID NO: 8), and a probe for amplifying the MALAT1 gene at a concentration of 0.15 μM (SEQ ID NO: 9). NO:9); a primer pair for amplifying the SPDEF gene at a concentration of 0.2 μM (SEQ ID NO:10, SEQ ID NO:11), a primer pair for amplifying the SPDEF gene at a concentration of 0.1 μM (SEQ ID NO:12); a primer pair for amplifying the HOCX6 gene at a concentration of 0.4 μM (SEQ ID NO:13, SEQ ID NO:14), a probe for amplifying the HOCX6 gene at a concentration of 0.08 μM (SEQ ID NO:15); a primer pair for amplifying the KLK3 gene at a concentration of 0.3 μM (SEQ ID NO:16, SEQ ID NO:17), a probe for amplifying the KLK3 gene at a concentration of 0.25 μM (SEQ ID NO:18); a primer pair for amplifying the DLX1 gene at a concentration of 0.4 μM (SEQ ID NO:19, SEQ ID NO:20), a probe for amplifying the DLX1 gene at a concentration of 0.08 μM (SEQ ID NO: NO:21); a primer pair for amplifying the PSMA gene at a concentration of 0.4 μM (SEQ ID NO:22, SEQ ID NO:23), a primer pair for amplifying the PSMA gene at a concentration of 0.08 μM (SEQ ID NO:24); a primer pair for amplifying the PCA3 gene at a concentration of 0.3 μM (SEQ ID NO:25, SEQ ID NO:26), a probe for amplifying the PCA3 gene at a concentration of 0.15 μM (SEQ ID NO:27); a primer pair for amplifying the TTTY15-USP9Y gene at a concentration of 0.2 μM (SEQ ID NO:28, SEQ ID NO:29), a probe for amplifying the TTTY15-USP9Y gene at a concentration of 0.08 μM (SEQ ID NO:30).

[0157] In this embodiment, the fluorescent group of the probe shown in SEQ ID NO:3 is FAM, and the quencher group is BHQ1; the fluorescent group shown in SEQ ID NO:6 is ROX, and the quencher group is BHQ2; the fluorescent group of the probe of SEQ ID NO:9 is CY5; the fluorescent group shown in SEQ ID NO:12 is HEX, and the quencher group of the probe is MGB; the fluorescent group of the probe shown in SEQ ID NO:15 is FAM, and the quencher group is BHQ1; the fluorescent group shown in SEQ ID NO:18 is HEX, and the quencher group is BHQ1; the fluorescent group of the probe of SEQ ID NO:21 is ROX, and the quencher group is BHQ2; the fluorescent group of the probe shown in SEQ ID NO:24 is FAM, and the quencher group is BHQ1; the fluorescent group shown in SEQ ID NO:27 is HEX, and the quencher group is BHQ1; the fluorescent group of the probe of SEQ ID NO:30 is CY5, and the quencher group is BHQ2; see Table 1 for some PCR amplification systems.

[0158] Table 1 PCR amplification reaction system

[0159]

[0160]

[0161] The PCR reaction solution is composed of a mixture of the above primers and probes, and a PCR buffer containing magnesium ions and dA / G / C / UTPs necessary for the PCR reaction.

[0162] In addition, the kit also includes an enzyme mixture consisting of reverse transcriptase, DNA polymerase and UNG enzyme.

[0163] When preparing the PCR amplification reaction solution, the formula is: 18.5 μl of the PCR reaction solution containing the primer and probe combination of the above markers per test, 1.5 μl of the enzyme mixture per test, 10 μl of the sample to be tested per test, and the total volume is 30 μl.

[0164] After the reagents were prepared, they were placed in the ABI7500 fluorescence quantitative PCR instrument for reaction, and the PCR reaction conditions were set according to Table 2.

[0165] Table 2 PCR amplification reaction conditions

[0166]

[0167]

[0168] After the PCR reaction, the Ct value of each RNA target was analyzed using ABI7500 supporting software. Fig. 9 , Fig.10 , Fig.11 These are the amplification curves of reaction combination 1, reaction combination 2, and reaction combination 3 for prostate cancer positive samples. Fig.12 , Fig.13 and Fig.14 The amplification curves of reaction combination 1, reaction combination 2 and reaction combination 3 for prostate cancer negative samples.

[0169] Example 2 Screening and model construction of urine exosome marker combination for prostate cancer detection

[0170] This embodiment provides a method for screening a combination of urine exosome markers for prostate cancer detection and constructing a prediction model, as well as statistical verification of patient samples.

[0171] In this study, samples were used if the following criteria were met: 1) biological males aged ≥40 years; 2) planned or had undergone serum PSA testing in this hospital; 3) planned to undergo prostate puncture / tissue biopsy and samples were collected before the biopsy.

[0172] According to the above criteria, this study recruited a total of 343 patients as training set samples, and the sample statistics are as follows:

[0173] PSA (ng / mL) Non-prostate cancer Prostate cancer total <4 65 5 70 4~20 144 41 185 >20 20 68 88 total 229 114 343

[0174] The screening and prediction model construction methods of the above biomarker combination are as follows:

[0175] (1) The above 343 samples were enriched and purified for exosomes using the method described in the patent application (CN202280000660). Exosome biomarker extraction and RT-qPCR detection were performed using technical means known in the art to obtain the detection Ct value of exosome biomarkers. The biomarkers include at least AMACR, FOXA1, MALAT1, and SPDEF.

[0176] (2) Analysis of biomarker mRNA expression levels and normalization of gene expression levels.

[0177] (3) Screening of differentially expressed genes. The normalized expression differences of genes such as AMACR, FOXA1, and MALAT1 in 229 non-prostate cancer samples and 114 prostate cancer samples were analyzed using the t-test method. Figure 6 As shown, the targets DLX1, HOCX6, FOXA1, MALAT1, PSMA, AMACR, PCA3, and TTTY15-USP9Y have significant differences between cancer patients and non-cancer (including healthy) people, and have certain diagnostic value for prostate cancer.

[0178] (4) Based on the significantly differentially expressed genes, logistic regression was used to evaluate the diagnostic performance of different markers or marker combination models. The results are shown in Table 3 below:

[0179] Table 3 Performance of different markers or marker combinations

[0180] Target combination Internal reference gene AUC Sensitivity Specificity AMACR+FOXA1 SPDEF 0.8069 63.5% 86.7% AMACR+FOXA1+MALAT1 SPDEF 0.9638 91.8% 88.7% AMACR+FOXA1+PSMA SPDEF 0.9541 93.6% 85.4% AMACR+FOXA1+PCA3 SPDEF 0.9307 91.2% 83.7% AMACR+FOXA1+DLX1 SPDEF 0.9216 89.9% 80.1% AMACR+FOXA1+HOCX6 SPDEF 0.9146 91.6% 79.5% AMACR+FOXA1+TTTY15-USP9Y SPDEF 0.9085 89.3% 74.9% AMACR+MALAT1 SPDEF 0.7916 77.7% 74.2% AMACR+MALAT1+PCA3 SPDEF 0.9347 90.0% 81.3% AMACR+MALAT1+DLX1 SPDEF 0.9227 89.2% 85.5% AMACR+MALAT1+HOCX6 SPDEF 0.9150 74.9% 88.8% AMACR+MALAT1+PSMA SPDEF 0.9033 83.7% 84.6% AMACR+MALAT1+TTTY15-USP9Y SPDEF 0.8912 80.0% 87.4%

[0181] In the logistic regression analysis, the prediction model of three targets AMACR+FOXA1+MALAT1 and internal reference SPDEF, e.g. Figure 1 The maximum AUC is 0.9638, and its sensitivity and specificity for diagnosing prostate cancer are 91.8% and 88.7%, respectively.

[0182] The present invention obtains random urine samples through a non-invasive method. DRE is not required before urine sample collection, and cell precipitation does not need to be separated from the urine sample. By combining the detection of prostate cancer-related gene expression, the tumor detection rate can be significantly improved, which has the characteristics of non-invasive, accurate and rapid.

[0183] Example 3 Application of prostate cancer prediction model in validation set

[0184] This embodiment provides a method for using a urine-based early screening model for prostate cancer, and can also be used to verify the accuracy of the urine-based prostate cancer prediction model provided in Example 2.

[0185] The above-mentioned kit, method and logistic regression formula were used to analyze 170 urine samples with PSA between 4 and 20 ng / mL from patients in the Urology Department of Tongji Hospital, Wuhan.

[0186] According to the hospital's clinical biopsy and pathological diagnosis results, there were 62 urine specimens for prostate cancer and 108 urine specimens for non-prostate cancer. Based on the derived logistic regression calculation formula, a comprehensive score was calculated using a proprietary algorithm to assess the risk of prostate cancer in 170 patients. The test results of the validation set are shown in Tables 4 and 5.

[0187] Table 4 Validation set performance of different markers or marker combinations

[0188] Target combination Internal reference gene AUC Sensitivity Specificity AMACR+FOXA1 SPDEF 0.7501 62.2% 80.1% AMACR+FOXA1+MALAT1 SPDEF 0.9026 85.5% 82.4% AMACR+FOXA1+PSMA SPDEF 0.8990 85.8% 78.5% AMACR+FOXA1+PCA3 SPDEF 0.8767 88.2% 72.4% AMACR+FOXA1+DLX1 SPDEF 0.8775 84.8% 79.6% AMACR+FOXA1+HOCX6 SPDEF 0.8698 83.7% 75.4% AMACR+FOXA1+TTTY15-USP9Y SPDEF 0.8481 70.0% 88.3% AMACR+MALAT1 SPDEF 0.7302 61.7% 80.0% AMACR+MALAT1+PCA3 SPDEF 0.8894 74.9% 90% AMACR+MALAT1+DLX1 SPDEF 0.8776 76.3% 88.7% AMACR+MALAT1+HOCX6 SPDEF 0.8625 86.1% 78.6% AMACR+MALAT1+PSMA SPDEF 0.8566 78.8% 85.3% AMACR+MALAT1+TTTY15-USP9Y SPDEF 0.8550 77.2% 86.6%

[0189] Table 5 Diagnostic performance of target combination AMACR+FOXA1+MALAT1 compared with pathological results

[0190]

[0191]

[0192] Sensitivity = 53 / 62 = 85.5%;

[0193] Specificity = 89 / 108 = 82.4%;

[0194] Total compliance rate = (53 + 89) / 170 = 83.5%;

[0195] like Figure 5 As shown in the figure, when PSA was between 4 and 20 ng / mL, the AUC was 0.6697, and in the same range, the AUC of the exosomal marker combination AMACR+FOXA1+MALAT1 was 0.9026, indicating that the diagnostic efficacy of the exosomal marker combination was better.

[0196] The accuracy of the early screening model for prostate cancer was verified using clinical samples, and the results showed that it was basically consistent with the previous data and could meet the requirements of clinical testing. It can eliminate unnecessary puncture biopsies for patients and reduce their pain.

[0197] The extraction of exosome samples is convenient, fast, with minimal risk and low cost, which can relieve pain for patients. Exosomes can be used to monitor cancer treatment results or monitor cancer recurrence, increase the detection rate of prostate cancer in high-risk groups, and discover early prostate cancer; reduce the prostate cancer mortality rate in the screened population without affecting the quality of life of the screened population.

[0198] The present invention illustrates the process method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned process steps, that is, it does not mean that the present invention must rely on the above-mentioned process steps to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of the raw materials selected by the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A urine exosome marker combination for prostate cancer detection, characterized in that: The markers include AMACR and internal reference genes, and one, two or three genes selected from FOXA1, MALAT1, DLX1, HOCX6, PSMA, PCA3, and TTTY15-USP9Y.

2. The marker combination according to claim 1, characterized in that: The markers include AMACR and internal reference genes, and one or two genes selected from FOXA1 and MALAT1.

3. The marker combination according to claim 2, characterized in that: The markers are AMACR, internal reference gene, FOXA1 and MALAT1.

4. The marker combination according to any one of claims 1 to 3, characterized in that: The internal reference gene is selected from one of SPDEF and KLK3.

5. An amplification primer set for amplifying the urine exosome marker according to claim 1, characterized in that: The primer set includes: a primer for amplifying AMACR, whose upstream primer sequence is shown in SEQ ID NO:1, and whose downstream primer sequence is shown in SEQ ID NO:2; a primer for amplifying FOXA1, whose upstream primer sequence is shown in SEQ ID NO:4, and whose downstream primer sequence is shown in SEQ ID NO:5; a primer for amplifying MALAT1, whose upstream primer sequence is shown in SEQ ID NO:7, and whose downstream primer sequence is shown in SEQ ID NO:8; a primer for amplifying HOCX6, whose upstream primer sequence is shown in SEQ ID NO:13, and whose downstream primer sequence is shown in SEQ ID NO:14; a primer for amplifying DLX1, whose upstream primer sequence is shown in SEQ ID NO:19, and whose downstream primer sequence is shown in SEQ ID NO:20; a primer for amplifying PSMA, whose upstream primer sequence is shown in SEQ ID NO:22, and whose downstream primer sequence is shown in SEQ ID NO:23; a primer for amplifying PCA3, whose upstream primer sequence is shown in SEQ ID NO:25, and whose downstream primer sequence is shown in SEQ ID NO:

26. NO:26; the primers for amplifying TTTY15-USP9Y, the upstream primer sequence of which is shown in SEQ ID NO:28, and the downstream primer sequence is shown in SEQ ID NO:

29.

6. The amplification primer set according to claim 5, characterized in that: The primer set further includes: a primer for amplifying an internal reference gene SPDEF, whose upstream primer sequence is shown in SEQ ID NO: 10, and whose downstream primer sequence is shown in SEQ ID NO: 11; a primer for amplifying an internal reference gene KLK3, whose upstream primer sequence is shown in SEQ ID NO: 16, and whose downstream primer sequence is shown in SEQ ID NO: 17;.

7. The amplification primer set according to claim 6, characterized in that: It also includes detection probes, wherein the probe sequence for detecting AMACR is shown in SEQ ID NO:3, the probe sequence for detecting FOXA1 is shown in SEQ ID NO:6, the probe sequence for detecting MALAT1 is shown in SEQ ID NO:9, the probe sequence for detecting SPDEF is shown in SEQ ID NO:12, the probe sequence for detecting HOCX6 is shown in SEQ ID NO:15, the probe sequence for detecting KLK3 is shown in SEQ ID NO:18, the probe sequence for detecting DLX1 is shown in SEQ ID NO:21, the probe sequence for detecting PSMA is shown in SEQ ID NO:24, the probe sequence for detecting PCA3 is shown in SEQ ID NO:27, and the probe sequence for detecting TTTY15-USP9Y is shown in SEQ ID NO:

30.

8. The amplification primer set according to claim 7, characterized in that: The detection probe is labeled with a fluorescent reporter group, and the fluorescent reporter group is selected from FAM, HEX, ROX, VIC, CY5, 5-TAMRA, TET, CY3 and JOE.

9. Use of the marker combination according to any one of claims 1 to 4 and the amplification primer set according to any one of claims 5 to 8 in preparing a detection reagent for detecting prostate cancer.

10. The use according to claim 9, characterized in that The detection is achieved by detecting exosomes in the patient's urine.

11. A kit for detecting prostate cancer, characterized in that: The kit comprises the amplification primer set according to any one of claims 5 to 8.

12. The kit according to claim 11, characterized in that The kit also includes a reagent for extracting urine exosomes.